GEP20135940B - Solid preparations - Google Patents

Solid preparations

Info

Publication number
GEP20135940B
GEP20135940B GEAP201012480A GEAP2010012480A GEP20135940B GE P20135940 B GEP20135940 B GE P20135940B GE AP201012480 A GEAP201012480 A GE AP201012480A GE AP2010012480 A GEAP2010012480 A GE AP2010012480A GE P20135940 B GEP20135940 B GE P20135940B
Authority
GE
Georgia
Prior art keywords
solid preparations
calcium antagonist
preparation
conta
gastro
Prior art date
Application number
GEAP201012480A
Other languages
English (en)
Inventor
Shigeyuki Marunaka
Makoto Fukuta
Wataru Hoshina
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43032637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GEP20135940(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of GEP20135940B publication Critical patent/GEP20135940B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
GEAP201012480A 2009-04-30 2010-04-28 Solid preparations GEP20135940B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009111381 2009-04-30
JP2010068625 2010-03-24

Publications (1)

Publication Number Publication Date
GEP20135940B true GEP20135940B (en) 2013-10-10

Family

ID=43032637

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP201012480A GEP20135940B (en) 2009-04-30 2010-04-28 Solid preparations

Country Status (24)

Country Link
EP (1) EP2424501A2 (ko)
JP (1) JP5666471B2 (ko)
KR (1) KR101797776B1 (ko)
CN (1) CN102481248B (ko)
AU (1) AU2010242308A1 (ko)
BR (1) BRPI1014388A2 (ko)
CA (1) CA2760073A1 (ko)
CL (1) CL2011002662A1 (ko)
CO (1) CO6470841A2 (ko)
CR (1) CR20110581A (ko)
DO (1) DOP2011000329A (ko)
EA (1) EA201171329A1 (ko)
EC (1) ECSP11011494A (ko)
GE (1) GEP20135940B (ko)
IL (1) IL215962A0 (ko)
MA (1) MA33280B1 (ko)
MX (1) MX2011011011A (ko)
MY (1) MY158158A (ko)
NZ (1) NZ596395A (ko)
PE (1) PE20120315A1 (ko)
SG (1) SG175794A1 (ko)
TW (1) TWI438201B (ko)
WO (1) WO2010126168A2 (ko)
ZA (1) ZA201108375B (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL236001B1 (pl) 2012-12-21 2020-11-30 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję
KR101535586B1 (ko) * 2014-08-01 2015-07-09 에스케이케미칼주식회사 무정형 또는 열역학적 준 안정형 리바록사반을 포함하는 약학 제제
WO2016122256A1 (ko) * 2015-01-30 2016-08-04 씨제이헬스케어 주식회사 칸데사르탄 및 암로디핀을 포함하는 약제학적 조성물
CN106668016B (zh) * 2015-11-11 2020-06-23 江苏先声药业有限公司 阿齐沙坦和苯磺酸氨氯地平组合物的固体制剂及其制备方法
JP2017210435A (ja) * 2016-05-25 2017-11-30 ダイト株式会社 イルベサルタン及びアムロジピンベシル酸塩配合錠の製造方法
JP2019001782A (ja) * 2017-06-14 2019-01-10 東和薬品株式会社 二層錠
JP7101464B2 (ja) * 2017-09-28 2022-07-15 エルメッド株式会社 アジルサルタン又はその塩及びアムロジピン又はその塩含有錠剤の品質向上方法、並びにアジルサルタン又はその塩及びアムロジピン又はその塩含有錠剤及びその製造方法
CN108210472A (zh) * 2017-12-15 2018-06-29 蚌埠丰原医药科技发展有限公司 一种西尼地平固体分散体片剂及其制备方法
CN108685925B (zh) * 2018-05-15 2019-12-06 徐州医科大学 一种化合物AB-38b在制备治疗糖尿病肾病药物方面的应用
JP2020075869A (ja) * 2018-11-05 2020-05-21 日本ケミファ株式会社 カルシウム拮抗剤及びアンジオテンシンｉｉ受容体拮抗剤を有効成分として含有する錠剤
JP2020090471A (ja) * 2018-12-07 2020-06-11 ニプロ株式会社 アジルサルタン及びアムロジピンを含有する医薬組成物及びその製造方法
JP7206872B2 (ja) * 2018-12-07 2023-01-18 ニプロ株式会社 アジルサルタン及びアムロジピンを含有する医薬組成物及びその製造方法
JP7441105B2 (ja) 2020-03-31 2024-02-29 日本ジェネリック株式会社 アジルサルタン及びアムロジピンベシル酸塩を含有するフィルムコーティング錠

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2814513B2 (ja) * 1988-02-03 1998-10-22 吉富製薬株式会社 溶出性の改良された製剤組成物
JP3057471B2 (ja) * 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
US20030187023A1 (en) 2000-07-17 2003-10-02 Keiji Kubo Sulfone derivatives, process for their production and use thereof
EP1369130A1 (en) * 2001-03-16 2003-12-10 Takeda Chemical Industries, Ltd. Process for producing sustained release preparation
AU2002349673A1 (en) * 2001-12-03 2003-06-17 Takeda Chemical Industries, Ltd. Insulin resistance improving agents
TW200306868A (en) * 2002-05-22 2003-12-01 Shionogi & Co Composition of hardly soluble medicine with improved solubility
AU2003284596A1 (en) 2002-11-22 2004-06-18 Takeda Pharmaceutical Company Limited Imidazole derivative, process for producing the same, and use
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical THIAZOLINE DERIVATIVE AND ITS USE
CA2550012A1 (en) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same and use
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
JP2006321726A (ja) * 2005-05-17 2006-11-30 Sysmex Corp 錠剤の溶出性調整方法
TWI407978B (zh) * 2005-06-27 2013-09-11 Sankyo Co 濕粒狀藥物之製備方法
KR20130135994A (ko) * 2005-06-27 2013-12-11 다이이찌 산쿄 가부시키가이샤 안지오텐신 ⅱ 수용체 길항제 및 칼슘 채널 차단제를 함유한 약학 제제
DE102005031577A1 (de) * 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
CN101652139A (zh) * 2007-03-29 2010-02-17 第一三共株式会社 药物组合物
AR073380A1 (es) * 2008-09-25 2010-11-03 Takeda Pharmaceutical Composicion farmaceutica solida. comprimido multicapa

Also Published As

Publication number Publication date
EP2424501A2 (en) 2012-03-07
CN102481248A (zh) 2012-05-30
JP5666471B2 (ja) 2015-02-12
MA33280B1 (fr) 2012-05-02
IL215962A0 (en) 2012-01-31
JP2012525323A (ja) 2012-10-22
ECSP11011494A (es) 2011-12-30
PE20120315A1 (es) 2012-04-07
KR101797776B1 (ko) 2017-11-14
BRPI1014388A2 (pt) 2016-04-05
TW201041873A (en) 2010-12-01
KR20120026060A (ko) 2012-03-16
CN102481248B (zh) 2013-12-11
CR20110581A (es) 2012-01-19
CL2011002662A1 (es) 2012-06-15
SG175794A1 (en) 2011-12-29
CO6470841A2 (es) 2012-06-29
TWI438201B (zh) 2014-05-21
NZ596395A (en) 2013-06-28
DOP2011000329A (es) 2011-11-15
WO2010126168A3 (en) 2011-03-03
MX2011011011A (es) 2011-11-02
MY158158A (en) 2016-09-15
EA201171329A1 (ru) 2012-05-30
ZA201108375B (en) 2013-01-30
AU2010242308A1 (en) 2011-12-01
WO2010126168A2 (en) 2010-11-04
CA2760073A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
GEP20135940B (en) Solid preparations
IL272236A (en) Preparations and methods for preparing drugs that are hardly soluble in water with increased stability
WO2009066152A3 (en) Haloallylamine inhibitors of ssao/vap-1 and uses therefor
GEP20135992B (en) Sulfonamide derivatives
HRP20221304T1 (hr) Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
WO2009016460A8 (en) Pyrazole compounds and their use as raf inhibitors
WO2011056985A3 (en) Substituted heterocyclic compounds
WO2008066899A3 (en) Nanoparticulate formulations and methods for the making and use thereof
WO2009074950A3 (en) Thiophene derivatives as agonists of s1p1/edg1
EA200970149A1 (ru) Производные n-(аминогетероарил)-1h-индол-2-карбоксамидов, их получение и их применение в терапии
WO2010120994A3 (en) Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
WO2010114405A3 (en) Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
NZ606250A (en) Methods of inhibition of protein fucosylation in vivo using fucose analogs
WO2010092090A3 (en) Novel salts of sitagliptin
MX340360B (es) Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas.
EA201170983A1 (ru) Производные тиадиазолов и оксадиазолов, их получение и их применение в терапии
MY159492A (en) Solid pharmaceutical formulation with delayed release
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
WO2007110834A3 (en) Malate salts, and polymorphs of (3s,5s)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid
EA201171270A1 (ru) ПРИМЕНЕНИЕ НИФУРАТЕЛА В ЛЕЧЕНИИ ИНФЕКЦИЙ, ВЫЗВАННЫХ ВИДОМ Atopobium
TN2012000105A1 (en) Spirolactam derivatives and uses of same
EP1883619B8 (en) Process of preparation of substituted tetrafluorobenzylaniline compound and its pharmaceutically approved salts
WO2006129160A3 (en) Stable aqueous oral solution of risperidone
EA201001870A1 (ru) Новые кристаллические формы рабепразола натрия
GB0622846D0 (en) Preparation of tissue for meniscal implantation